AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14977698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low α1 antitrypsin (α1-AT) levels
Number of subjects: 5629
Study 14977698 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygosity of the α1 antitrypsin (α1-AT) Pi genotypes MS or MZ
Number of subjects: 5629
Study 12599994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 60 g/day soy protein
Number of subjects: 0
Study 12599994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 30 g/day soy protein
Number of subjects: 0
Study 12599994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 45 g/day soy protein
Number of subjects: 0
Study 9835668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure bandage
Number of subjects: 1075
Study 9835668 — intervention group
Group type: COMPARATOR
Intervention: No bandage
Number of subjects: 1075
Study 8563662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CB)
Number of subjects: 117
Study 8563662 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal therapy (PI)
Number of subjects: 117
Study 8563662 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight sessions of therapy
Number of subjects: 117
Study 8563662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sixteen sessions of therapy
Number of subjects: 117
Study 2682710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydiphen
Number of subjects: 45
Study 2682710 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 45
Study 8188 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 8188 — intervention group
Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 12
Study 31432657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with periprosthetic infection (n=50)
Number of subjects: 150
Study 31432657 — intervention group
Group type: COMPARATOR
Intervention: Patients without infectious complications (n=100)
Number of subjects: 150
Study 30926189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (0.75 mg/kg)
Number of subjects: 120
Study 30926189 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (saline solution)
Number of subjects: 120
Study 30926189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 120
Study 30926189 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 120
Study 28472247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 158
Study 26147544 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated workplace safety and smoking cessation program
Number of subjects: 328
Study 26147544 — intervention group
Group type: COMPARATOR
Intervention: Commercial databases for recruitment
Number of subjects: 328
Study 23974036 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a twelve-month SUMMIT program participation with personal support
Number of subjects: 236
Study 23974036 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a twelve-month SUMMIT program participation without personal support
Number of subjects: 236
Study 23974036 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 236
Study 21252259 — intervention group
Group type: EXPERIMENTAL
Intervention: High quartile of soluble CD14 (sCD14) levels
Number of subjects: 275
Study 21252259 — intervention group
Group type: COMPARATOR
Intervention: Intestinal fatty acid binding protein (I‐FABP), lipopolysaccharide (LPS), soluble CD14 (sCD14)
Number of subjects: 275
Study 21252259 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin core antibody (EndoCAb)
Number of subjects: 275
Study 21252259 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 275
Study 19503012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg daily for 5 days, then tapering for 5 days plus placebo
Number of subjects: 829
Study 19503012 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1,000 mg 3 times daily for 7 days plus placebo
Number of subjects: 829
Study 19503012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus valacyclovir
Number of subjects: 829
Study 19503012 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 829
Study 19503012 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 829
Study 19503012 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pain at Days 11 to 17
Number of subjects: 829
Study 16877985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (ATCC 53103)
Number of subjects: 132
Study 16877985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12544447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (400 mmol/day)
Number of subjects: 25
Study 12544447 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (10 mmol/day)
Number of subjects: 25
Study 12544447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress response
Number of subjects: 25
Study 12544447 — intervention group
Group type: COMPARATOR
Intervention: Low salt (7.8 +/- 0.9 to 11.2 +/- 1.4 ml/min per 100 ml)
Number of subjects: 25
Study 12544447 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt (8.5 +/- 1.2 to 10.4 +/- 1.3 ml/min per 100 ml)
Number of subjects: 25
Study 10871469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist therapy
Number of subjects: 120
Study 10871469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9062479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose T3 treatment for 63 days
Number of subjects: 7
Study 9062479 — intervention group
Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 7
Study 9062479 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 7
Study 9062479 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 treatment
Number of subjects: 7
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic definitions of restenosis
Number of subjects: 125
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrent symptoms
Number of subjects: 125
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: History of recurrent angina or positive exercise testing
Number of subjects: 125
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive exercise testing in patients with angina
Number of subjects: 125
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of 2 standard deviations definition
Number of subjects: 125
Study 8269186 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of 50% absolute gain definition
Number of subjects: 125
Study 3534021 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin (retinoic acid and Retin-A) delivered by cervical cap and inert collagen sponge system
Number of subjects: 0
Study 29959297 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek P60
Number of subjects: 30
Study 29959297 — intervention group
Group type: EXPERIMENTAL
Intervention: X-tra fil
Number of subjects: 30
Study 29959297 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Fusion x-tra
Number of subjects: 30
Study 26725102 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 498
Study 26725102 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting balloons (DEB)
Number of subjects: 498
Study 24584048 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO half‐squats (3 sets of 3‐second maximal isometric)
Number of subjects: 14
Study 24584048 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC half‐squats (9.3 +/‐ 1.5 repetitions against 70% of 1RM)
Number of subjects: 14
Study 24584048 — intervention group
Group type: EXPERIMENTAL
Intervention: CON half‐squats (7.5 +/‐ 1.2 repetitions against 90% of 1RM)
Number of subjects: 14
Study 24584048 — intervention group
Group type: COMPARATOR
Intervention: CTRL (rest for 10 minutes)
Number of subjects: 14
Study 22425057 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 47
Study 22425057 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 47
Study 20585000 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day modafinil
Number of subjects: 20
Study 20585000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20585000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 h/night)
Number of subjects: 20
Study 18853069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolyltriazole exposure during double-blind provocation test
Number of subjects: 1
Study 18853069 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalworking fluids exposure during first provocation test
Number of subjects: 1
Study 16279153 — intervention group
Group type: EXPERIMENTAL
Intervention: ISWT + PLB
Number of subjects: 69
Study 16279153 — intervention group
Group type: COMPARATOR
Intervention: Baseline walk (non-PLB)
Number of subjects: 69
Study 16279153 — intervention group
Group type: COMPARATOR
Intervention: ISWT (breathing normally)
Number of subjects: 69
Study 11985939 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid supplementation
Number of subjects: 0
Study 11985939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10100363 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP spray at 20 mcg/day for 6 weeks
Number of subjects: 237
Study 10100363 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP spray at 30 mcg/day for 6 weeks
Number of subjects: 237
Study 10100363 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP spray at 20 mcg/day for 2 weeks, then 30 mcg/day for 2 weeks after washout
Number of subjects: 237
Study 10100363 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP spray at 30 mcg/day for 2 weeks, then 20 mcg/day for 2 weeks after washout
Number of subjects: 237
Study 10100363 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP spray at doses ranging from 20 to 40 mcg/day
Number of subjects: 237
Study 8682086 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus IFN
Number of subjects: 40
Study 8682086 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus thymomodulin
Number of subjects: 40
Study 8682086 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 40
Study 8682086 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus IFN and thymomodulin
Number of subjects: 40
Study 2351902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucolyte‐2
Number of subjects: 33
Study 2351902 — intervention group
Group type: COMPARATOR
Intervention: Conventional infusion
Number of subjects: 33
Study 6158428 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant stimuli (diffuse and grating light flashes)
Number of subjects: 6
Study 31973934 — intervention group
Group type: EXPERIMENTAL
Intervention: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Number of subjects: 155
Study 31973934 — intervention group
Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 155
Study 31973934 — intervention group
Group type: EXPERIMENTAL
Intervention: Coolant spray
Number of subjects: 155
Study 31221698 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 150
Study 31221698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 150
Study 30243419 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 100
Study 30243419 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 100
Study 26330300 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration (FR) program
Number of subjects: 44
Study 26330300 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 44
Study 24556493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius WB21 (2.0 × 10(9) colony‐forming units per day)
Number of subjects: 0
Study 24556493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22465116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP)
Number of subjects: 71
Study 22465116 — intervention group
Group type: COMPARATOR
Intervention: COC nonusers (control group)
Number of subjects: 71
Study 20099364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in RCC patients before surgery
Number of subjects: 36
Study 20099364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in antiangiogenically treated RCC patients
Number of subjects: 36
Study 20099364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in papillary RCC
Number of subjects: 36
Study 20099364 — intervention group
Group type: COMPARATOR
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) in normal kidneys
Number of subjects: 36
Study 17963466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol and ketamine
Number of subjects: 8
Study 17963466 — intervention group
Group type: COMPARATOR
Intervention: Propofol monotherapy
Number of subjects: 8
Study 17963466 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of ketamine added to propofol
Number of subjects: 8
Study 16131580 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 (titrated to maintain low TSH)
Number of subjects: 25
Study 16131580 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 (titrated to restore euthyroidism)
Number of subjects: 25
Study 11853247 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-sealant (Concise) with acid etch and tooth preparation
Number of subjects: 30
Study 11853247 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorative material (F2000) with acid etch, bonding agent, and tooth preparation
Number of subjects: 30
Study 11853247 — intervention group
Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and no tooth preparation
Number of subjects: 30
Study 11853247 — intervention group
Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and tooth preparation
Number of subjects: 30
Study 11853247 — intervention group
Group type: COMPARATOR
Intervention: Compomer restorative material (F2000) with bonding agent and without enameloplasty
Number of subjects: 30
Study 11853247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant with acid etching and enameloplasty
Number of subjects: 30
Study 11853247 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer with acid etching and bonding agent
Number of subjects: 30
Study 11853247 — intervention group
Group type: EXPERIMENTAL
Intervention: Enameloplasty and acid etching
Number of subjects: 30
Study 10885910 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 256
Study 10885910 — intervention group
Group type: COMPARATOR
Intervention: infusional 5-FU
Number of subjects: 256
Study 8950882 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg per day
Number of subjects: 15
Study 8950882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8950882 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 15
Study 1827053 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 20 micrograms.kg‐1
Number of subjects: 60
Study 1827053 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 microgram.kg‐1
Number of subjects: 60
Study 7039533 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (30 to 60 mg orally for six days before operation)
Number of subjects: 50
Study 7039533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coenzyme Q10)
Number of subjects: 50
Study 31763265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic turbinoplasty
Number of subjects: 60
Study 31763265 — intervention group
Group type: COMPARATOR
Intervention: Conventional partial inferior turbinectomy
Number of subjects: 60
Study 28835059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1) + flurbiprofen axetil 200 mg)
Number of subjects: 100
Study 28835059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (hydromorphone hydrochloride 2 μg·kg(‐1)·h(‐1))
Number of subjects: 100
Study 28835059 — intervention group
Group type: COMPARATOR
Intervention: Group C (hydromorphone hydrochloride 1 μg·kg(‐1)·h(‐1))
Number of subjects: 100
Study 28835059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 100
Study 28835059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 100
Study 28835059 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 100
Study 25676147 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire stent retriever (roll-in period)
Number of subjects: 0
Study 25676147 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire stent retriever (randomized phase)
Number of subjects: 0
Study 25676147 — intervention group
Group type: COMPARATOR
Intervention: Solitaire stent retriever
Number of subjects: 0
Study 24770960 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol SPN (1 ml of absolute alcohol injected under CT guidance)
Number of subjects: 42
Study 22497427 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 158
Study 22497427 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 158
Study 19841919 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 6
Study 19841919 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 6
Study 18020851 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to use microbicides
Number of subjects: 531
Study 16168806 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous myocardial laser (PML)
Number of subjects: 82
Study 16168806 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 82
Study 12072587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 84 microg every 12 hours
Number of subjects: 8
Study 12072587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12072587 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 8
Study 10416552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity residential exercise training program
Number of subjects: 25
Study 10416552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 7587855 — intervention group
Group type: COMPARATOR
Intervention: AC137 infusion (50 micrograms/h) during a standardized Sustacal meal (350 kcal) challenge.
Number of subjects: 24
Study 7587855 — intervention group
Group type: COMPARATOR
Intervention: AC137 infusion (steady-state concentrations of 234 +/- 16 pmol/l) during an intravenous glucose load (300 mg/kg).
Number of subjects: 24
Study 2210097 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mM glucose-sodium chloride solution
Number of subjects: 0
Study 2210097 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose concentrations greater than 250 mM
Number of subjects: 0
Study 2210097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal glucose-stimulated water absorption
Number of subjects: 0
Study 2210097 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal glucose absorption
Number of subjects: 0
Study 2210097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal glucose absorption
Number of subjects: 0
Study 6951257 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (up to six times, 30 min per session)
Number of subjects: 30
Study 6951257 — intervention group
Group type: COMPARATOR
Intervention: Full coverage splints at night for 6 weeks
Number of subjects: 30
Study 31568868 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve interventions (TTVI)
Number of subjects: 1651
Study 29276868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline mixed with 3% hypertonic saline
Number of subjects: 378
Study 29276868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 378
Study 29276868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline
Number of subjects: 378
Study 29276868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 378
Study 29276868 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9% NaCl)
Number of subjects: 378
Study 26547414 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-0.6 (formula with 0.6 g/L bLf)
Number of subjects: 480
Study 26547414 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-1.0 (formula with 1.0 g/L bLf)
Number of subjects: 480
Study 26547414 — intervention group
Group type: COMPARATOR
Intervention: Control (cow's milk-based formula)
Number of subjects: 480
Study 23340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with bevacizumab
Number of subjects: 363
Study 23340303 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel without bevacizumab (control)
Number of subjects: 363
Study 23340303 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with or without bevacizumab
Number of subjects: 363
Study 21795437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss intervention
Number of subjects: 78
Study 21795437 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain (≥2 kg)
Number of subjects: 78
Study 19276858 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg of 19‐norandrostenedione
Number of subjects: 20
Study 19276858 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg of 19‐norandrostenedione
Number of subjects: 20
Study 19276858 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microg of 19‐norandrostenedione
Number of subjects: 20
Study 19276858 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of 19‐norandrostenedione
Number of subjects: 20